VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...
The global smart syringes market is poised for substantial growth, projected to escalate from a valuation of US$ 10.22 billion in 2024 to US$ 24.37 billion by 2033, reflecting an impressive CAGR of 10 ...
Dublin, May 07, 2021 (GLOBE NEWSWIRE) -- The "Disposable Syringes Market Size, Trends & Analysis, By Product Type, By Application, By End Use, And By Region, Global Forecast To 2028" report has been ...
The Global Prefilled Syringes Market is expected to witness a high single-digit growth rate by 2027. The growth of the prefilled syringes market is driven by an increasing prevalence of diverse ...
LE PONT-DE-CLAIX, France, Sept. 18, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak™ ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...
Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback